Lisa H. Lancaster, MD
Medical Director, Interstitial Lung Disease Program
Professor of Medicine
Division of Allergy, Pulmonary and Critical Care Medicine
Vanderbilt University Medical Center
Upon completion of this activity, participants should be able to:
- Differentiate idiopathic pulmonary fibrosis (IPF) from other common ILDs, such as connective tissue disease-associated ILD (CTD-ILD), accurately and efficiently using recommended clinical evaluation, radiologic testing, and pathologic testing as needed
- Apply evidence informing the use of antifibrotic therapy, nonpharmacologic strategies, and management of risk factors and comorbidities in patients with IPF to formulate treatment plans
- Individualize treatment of IPF based on patient characteristics and preferences, using shared decision-making
This activity is provided by Paradigm Medical Communications, LLC.
Held in collaboration with the Pulmonary Fibrosis Foundation.